THYQUIDITY is designed for consistent daily
administration of any medically appropriate dose1

With THYQUIDITY, your patients or their caregivers can administer
the prescribed dose individualized to their TSH goal

  • THYQUIDITY is a liquid oral solution with 100 mcg levothyroxine sodium per 5 mL (20 mcg per mL)
  • THYQUIDITY is supplied in a package of two 100 mL bottles. Based on the average daily dose, 1 prescription of THYQUIDITY should last an adult patient ~6 weeks. A bottle of THYQUIDITY can be used up to 8 weeks once opened*
THYQUIDITY (levothyroxine sodium) oral solution is a liquid oral solution with 100 mcg levothyroxine sodium per 5 mL (20 mcg per mL). Please see full Prescribing Information Including Boxed Warning.

Calibrated oral syringe provided by pharmacy.

  • THYQUIDITY is drawn from the bottle into a calibrated oral syringe provided by the pharmacy and administered directly into the mouth
  • Taken once daily on an empty stomach one half to one hour before breakfast
  • Administered at least 4 hours before or after drugs that are known to interfere with absorption

*Assuming the strength of levothyroxine sodium prescribed daily is 88 mcg (4.4 mL). With two 100 mL bottles included in a package of THYQUIDITY, it would take a patient ~45 days to finish.2

T4: thyroxine; TSH: thyroid-stimulating hormone.

A liquid formulation designed to deliver an individualized dose to patients1

Patient type
Starting dose
Dose adjustment and TSH measurement
Patient type
Otherwise healthy, nonelderly individuals who have been hypothyroid for only a short time (a few months)
Starting dose
1.6 mcg/kg/day
Dose adjustment and TSH measurement
Adjust by 12.5 to 25 mcg increments every 4 to 6 weeks until clinically euthyroid and TSH normalized
Patient type
Elderly patients or patients with underlying cardiac disease
Starting dose
12.5 to 25 mcg/day
Dose adjustment and TSH measurement
Increase dose every 6 to 8 weeks until clinically euthyroid and TSH normalized
Patient type
Patients with severe, long-standing hypothyroidism
Starting dose
12.5 to 25 mcg/day
Dose adjustment and TSH measurement
Adjust by 12.5 to 25 mcg increments every 2 to 4 weeks until clinically euthyroid and TSH normalized
Patient type
Pediatric patients
Starting dose
See Prescribing Information for age-specific dosing guidelines from age 0 to completion of puberty
Patient type
Pregnant patients with pre-existing primary hypothyroidism
Starting dose
THYQUIDITY dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at a minimum, during each trimester of pregnancy. Maintain serum TSH in the trimester-specific reference range
Patient type
Pregnant patients with new-onset hypothyroidism
Starting dose
Normalize thyroid function as rapidly as possible. Evaluate serum TSH every 4 weeks and adjust THYQUIDITY dosage until serum TSH is within the normal trimester-specific range
Patient type
Patients with well-differentiated thyroid cancer
Starting dose
Generally, TSH is suppressed to below 0.1 mIU per liter, and this usually requires a THYQUIDITY dose of >2 mcg/kg/day. However, in patients with high-risk tumors, the target level for TSH suppression may be lower

Microgram to milliliter conversion: mcg x 0.05 = mL or total mcg/20 = total mL of THYQUIDITY

Example: 60 mcg = 3.0 mL

†Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medical conditions (including pregnancy), concomitant medications, coadministered food, and the specific nature of the condition being treated.

‡Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect THYQUIDITY absorption.

T4: thyroxine; TSH: thyroid-stimulating hormone.

Please see the Prescribing Information for additional guidelines for dosing in specific patient populations.

Broad dosing flexibility

As a liquid, THYQUIDITY can help you meet patients’ individual
needs with flexible dosing adjustments1

Starting dose calculator for adults.
Levothyroxine dosing conversion by weight.
Starting dose calculator.
Levothyroxine tablet (mcg) to liquid (mL) conversion.

Healthy nonelderly adults (growth and puberty complete)
who have been hypothyroid for a short time (a few months)

Enter your patient’s
weight in pounds

Enter the desired
dose in micrograms

Refer to full Prescribing Information for dosing guidance at this weight.Refer to full Prescribing Information for dose guidance at this amount.

Recommended starting dose based on patient weight (1.6 mcg/kg).

Doses greater than 200 mcg per day are seldom required.

An inadequate response to daily doses of greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.

  • Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medical conditions (including pregnancy), concomitant medications, coadministered food, and the specific nature of the condition being treated. Peak therapeutic effect may not be attained for 4-6 weeks
  • Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect THYQUIDITY absorption
  • Adequacy of therapy is determined with periodic monitoring of TSH and/or T4 levels, as well as clinical status
RESOURCES AND SUPPORT

View materials and programs available to patients taking THYQUIDITY

INDICATION

Hypothyroidism

THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression

THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Limitations of Use

THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with THYQUIDITY may induce hyperthyroidism.

THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

IMPORTANT SAFETY INFORMATION

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

Please see full Prescribing Information including Boxed Warning.

You may report side effects to the FDA at 800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vertice Specialty Group at 800-470-6233 or email at medinfo.vertice@apcerls.com.

References: 1. THYQUIDITY (levothyroxine sodium) oral solution [package insert]. New Providence, NJ: Vertice Specialty Group: 12/2020. 2. Data on file. Vertice Specialty Group. IQVIA 2020 Levothyroxine sodium class utilization by dose strength.

INDICATION

Hypothyroidism

THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression

THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

IMPORTANT SAFETY INFORMATION

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

Coming Soon